Abstract

The recently recognized renal cell carcinomas (RCCs) associated with Xp11.2 translocations (TFE3 transcription factor gene fusions) are rare tumors predominantly reported in children. They comprise at least one-third of pediatric RCCs and only few adult cases have been reported. Here, we present a case of Xp11.2 translocation RCC in 26-year-old pregnant female. Her routine antenatal ultrasonography accidentally found a complex cystic right renal mass. Further radiologic studies revealed unilocular cyst with multiple mural nodules at inferior pole of right kidney, which was suspicious for RCC. She underwent right radical nephrectomy at 15 weeks gestation. Macroscopically, the cystic tumor was well encapsulated with multiple friable mural nodules on its inner surface. Microscopically, the tumor consisted of clear and eosinophilic/oncocytic voluminous cells arranged in papillary, trabecular, and nested/alveolar patterns. Occasional hyaline nodules and numerous psammoma bodies were present.Immunohistochemically, the tumor showed strong nuclear positivity for TFE3. Epithelial membrane antigen, CD10, and E-cadherin were strongly positive. Cytokeratin AE1/AE3, cytokeratin CAM-5.2, calveolin, and parvalbumin were moderately positive. Cytokeratin 7, renal cell carcinoma antigen, and colloidal iron were focally weakly positive. BerEP4 and carbonic anhydrase IX were negative. Cytogenetically, the tumor harbored a novel variant translocation involving chromosomes X and 19, t(X;19)(p11.2;q13.1). Interphase FISH analysis performed on cultured and uncultured tumor cells using a dual-color break-apart DNA probe within the BCL3 gene on 19q13.3 was negative for the BCL3 gene rearrangement. She received no adjuvant therapy, delivered a normal term baby five months later, and is alive without evidence of disease 27 months after diagnosis and surgery. Unlike most recently reported Xp11.2 translocation RCCs in adult patients with aggressive clinical course, this adult case occurring during pregnancy with a novel translocation involving chromosome 19 followed an indolent clinical course.

Highlights

  • Xp11.2 translocation renal cell carcinomas (RCCs) are defined by at least six different translocations involving the Xp11.2 chromosome, all of which result from gene fusions involving the TFE3 transcription factor gene, and their morphology and biological behavior are not widely recognized as yet [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24]

  • Macroscopic findings The right nephrectomy specimen was bivalved from the peripheral cortex towards the hilum to show a 5.5 × 4.5 × 3.5-cm well encapsulated, unilocular cystic tumor at the inferior pole of the kidney

  • Microscopic findings The renal tumor showed carcinomatous proliferation of malignant epithelial cells arranged in papillary (Figures 3A &3B), trabecular, and nested/alveolar (Figure 3C) patterns

Read more

Summary

Introduction

Xp11.2/TFE3 translocation renal cell carcinomas (RCCs), a recently classified distinct subtype, are rare tumors that usually affect children and adolescents [1,2,3,4,5,6,7,8], with only few reported adult cases to date [9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24]. Xp11.2 translocation RCCs are defined by at least six different translocations involving the Xp11.2 chromosome, all of which result from gene fusions involving the TFE3 transcription factor gene, and their morphology and biological behavior are not widely recognized as yet [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24] They typically have papillary and/or nested architecture, and are composed of cells with clear and/or eosinophilic voluminous cytoplasm [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24]. Only limited data are available far, they are believed to be rather indolent even when diagnosed at advanced stages [1,2,3,4,5,6,7,8], but there have been increasing recent reports of an aggressive clinical course in adult cases [9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call